Breast CancerTogetherNCT07499089
Together-Breast Cancer Support Platform
An observational study of Breast Cancer and Breast Cancer Survivors, run by Cedars-Sinai Medical Center at 1 site in United States.
Trial summary
The goal of this study is to evaluate the acceptability and engagement of a culturally tailored online peer-support program for Korean speaking breast cancer patients and survivors. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer, Breast Cancer Survivors
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2026to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of Korean American breast cancer patients and survivors. Participants include mentors (breast cancer survivors diagnosed at least two years prior and who have completed treatment or are on long-term maintenance therapy) and mentees (patients currently undergoing active breast cancer treatment). All participants are required to have access to a smartphone or computer and be able to participate in an online peer-support platform. Participants will be recruited through community outreach, referrals, and self-referral using a QR code-based screening process.
Who may be able to join
- Mentors:
- Age ≥ 18 years
- Self-identify as Korean
- Able to read, write, and speak both Korean and English
- Diagnosed with breast cancer ≥ 2 years prior to enrollment
- Completed active treatment or currently on long-term maintenance therapy
Show all 18Show fewer
- Access to a smartphone, computer, or similar device compatible with the study platform
- Willing to participate for at least 3 months
- Willing to complete required training and surveys
- Mentees:
- Age ≥ 18 years
- Self-identify as Korean
- Able to read, write, and speak Korean
- Diagnosed with breast cancer
- Currently receiving treatment (e.g., chemotherapy, radiation therapy, recent surgery, or endocrine therapy)
- Access to a smartphone, computer, or similar device compatible with the study platform
- Willing to participate for at least 3 months
- Willing to complete required surveys
Who cannot join
- Individuals who do not meet the inclusion criteria
- Individuals unable to use the online platform or required technology
- Individuals deemed non-compliant or inappropriate for participation based on investigator judgment (e.g., inability to complete study procedures)
- Mentees diagnosed with ductal carcinoma in situ (DCIS)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Cedars Siani Cancer
Los Angeles, California, 90048
Min Jung Sung, BA, 424-315-0709, minjung.sung@cshs.org
About this study
Official title: "Together": A Bilingual Online Platform Support Intervention Project for Korean Breast Cancer Survivors
The goal of this study is to evaluate the acceptability and engagement of a culturally tailored online peer-support program for Korean speaking breast cancer patients and survivors. The main questions it aims to answer are: 1) Is the peer-support program acceptable and sustainable in terms of engagement between mentors and mentees over a 12-week period? 2) Does participation in the program improve quality of life, psychological well-being (including anxiety and depression), and perceived social support?
Participants will include Korean speaking breast cancer survivors (mentors) and patients currently undergoing treatment (mentees). After enrollment and matching based on screening information, participants will engage in peer-support interactions through an online platform for 12 weeks. Surveys will be administered at baseline, mid-point, post-intervention, and optional 6-month follow-up to assess outcomes.
Read the detailed description
This study evaluates the acceptability and engagement of a culturally tailored online peer-support program for Korean speaking breast cancer patients and survivors, as well as its potential impact on psychosocial outcomes.
A total of 24 participants will be enrolled, including 8 mentors (breast cancer survivors diagnosed at least two years prior who have completed active treatment or are on long-term maintenance therapy) and 16 mentees (patients currently undergoing treatment).
Participants will be recruited through community outreach using study flyers with a QR code that links to an online eligibility screener. Individuals who complete the screener will be contacted by the study coordinator to confirm eligibility and complete the informed consent process prior to enrollment.
Mentors and mentees will be matched based on information collected from the screener, including demographic and clinical characteristics such as age group and cancer stage at diagnosis. Each mentor may be matched with up to two mentees.
Mentors will complete a structured training program prior to participation. All participants will engage in peer-support interactions through an online platform over a 12-week period, with a minimum expectation of at least one bidirectional interaction per week.
Data will be collected using REDCap. Participants will complete surveys at baseline, mid-intervention (weeks 4-5), and post-intervention (weeks 12-13), with an optional follow-up survey at 6 months.
Outcome measures include engagement metrics, quality of life, psychological well-being (including anxiety and depression), and perceived social support.
- Conditions
- Breast Cancer, Breast Cancer Survivors
- Keywords
- Breast Cancer Survivorship, Korean American, Online peer support,
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Mentors | Korean breast cancer survivors who complete mentor training and provide peer support to matched mentees through the Together online platform. | |
| Mentees | Korean breast cancer patients currently receiving treatment who are matched with trained mentors and participate in peer-support interactions through the Together online platform. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of peer-support platform engagement
Feasibility is defined as the proportion of mentor-mentee pairs achieving at least one bidirectional interaction per week for at least 8 out of 12 weeks during the study period.
Measured: Week 1 to Week 12
Secondary outcomes (3)
Change in quality of life (FACT-B score)
Quality of life will be assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire, which includes physical, social/family, emotional, and functional well-being domains.
Measured: Baseline to Week 12
Change in social/family well-being (FACT-B social/family subscale)
Social/family well-being will be assessed using the social/family well-being subscale of the FACT-B questionnaire.
Measured: Baseline to Week 12
Change in self-efficacy score
Self-efficacy will be assessed using the self-efficacy scale included in the study questionnaire administered at baseline, mid-study, and post-study.
Measured: Baseline to Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Mar 2026
- Study start1 Apr 2026 (estimated)
- Primary completion30 Apr 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cedars-Sinai Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jin Sun Bitar, Cedars-Sinai Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07499089
- Sponsor's protocol ID
- Study00003360
- Acronym
- Together
- Status last verified
- Mar 2026
- First submitted
- 24 Mar 2026
- Last updated
- 30 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No, individual participant data will not be made available to other researchers.
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- "Together": A Bilingual Online Platform Support Intervention Project for Korean Breast Cancer Survivors
- ClinicalTrials.gov ID
- NCT07499089
- Acronym / sponsor ID
- Together / Study00003360
- Conditions
- Breast Cancer, Breast Cancer Survivors
- Keywords
- Breast Cancer Survivorship, Korean American, Online peer support,
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Cedars-Sinai Medical CenterUniversity, hospital or other
- Study start
- 1 Apr 2026 (estimated)
- Primary completion
- 30 Apr 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 30 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to evaluate the acceptability and engagement of a culturally tailored online peer-support program for Korean speaking breast cancer patients and survivors. The main questions it aims to answer are: 1) Is the peer-support program acceptable and sustainable in terms of engagement between mentors and mentees over a 12-week period? 2) Does participation in the program improve quality of life, psychological well-being (including anxiety and depression), and perceived social support?
Participants will include Korean speaking breast cancer survivors (mentors) and patients currently undergoing treatment (mentees). After enrollment and matching based on screening information, participants will engage in peer-support interactions through an online platform for 12 weeks. Surveys will be administered at baseline, mid-point, post-intervention, and optional 6-month follow-up to assess outcomes.
Detailed description
This study evaluates the acceptability and engagement of a culturally tailored online peer-support program for Korean speaking breast cancer patients and survivors, as well as its potential impact on psychosocial outcomes.
A total of 24 participants will be enrolled, including 8 mentors (breast cancer survivors diagnosed at least two years prior who have completed active treatment or are on long-term maintenance therapy) and 16 mentees (patients currently undergoing treatment).
Participants will be recruited through community outreach using study flyers with a QR code that links to an online eligibility screener. Individuals who complete the screener will be contacted by the study coordinator to confirm eligibility and complete the informed consent process prior to enrollment.
Mentors and mentees will be matched based on information collected from the screener, including demographic and clinical characteristics such as age group and cancer stage at diagnosis. Each mentor may be matched with up to two mentees.
Mentors will complete a structured training program prior to participation. All participants will engage in peer-support interactions through an online platform over a 12-week period, with a minimum expectation of at least one bidirectional interaction per week.
Data will be collected using REDCap. Participants will complete surveys at baseline, mid-intervention (weeks 4-5), and post-intervention (weeks 12-13), with an optional follow-up survey at 6 months.
Outcome measures include engagement metrics, quality of life, psychological well-being (including anxiety and depression), and perceived social support.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Mentors | – | –Korean breast cancer survivors who complete mentor training and provide peer support to matched mentees through the Together online platform. |
| Mentees | – | –Korean breast cancer patients currently receiving treatment who are matched with trained mentors and participate in peer-support interactions through the Together online platform. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of Korean American breast cancer patients and survivors. Participants include mentors (breast cancer survivors diagnosed at least two years prior and who have completed treatment or are on long-term maintenance therapy) and mentees (patients currently undergoing active breast cancer treatment). All participants are required to have access to a smartphone or computer and be able to participate in an online peer-support platform. Participants will be recruited through community outreach, referrals, and self-referral using a QR code-based screening process.
Key inclusion criteria (18 listed)
- Age ≥ 18 years
- Self-identify as Korean
- Able to read, write, and speak both Korean and English
- Diagnosed with breast cancer ≥ 2 years prior to enrollment
- Completed active treatment or currently on long-term maintenance therapy
Key exclusion criteria (4 listed)
- Individuals who do not meet the inclusion criteria
- Individuals unable to use the online platform or required technology
- Individuals deemed non-compliant or inappropriate for participation based on investigator judgment (e.g., inability to complete study procedures)
- Mentees diagnosed with ductal carcinoma in situ (DCIS)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Feasibility of peer-support platform engagement
Time frame: Week 1 to Week 12
Feasibility is defined as the proportion of mentor-mentee pairs achieving at least one bidirectional interaction per week for at least 8 out of 12 weeks during the study period.
3 secondary outcomes
Change in quality of life (FACT-B score)
Time frame: Baseline to Week 12
Change in social/family well-being (FACT-B social/family subscale)
Time frame: Baseline to Week 12
Change in self-efficacy score
Time frame: Baseline to Week 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2026.
- Individual participant dataSharing planned: No. No, individual participant data will not be made available to other researchers.
Related trials for Breast Cancer
Not yet recruiting
Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening
Breast Cancer Screening, Breast Cancer Awareness
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
Not yet recruitingPhase 2
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
Breast Neoplasms, Advanced Breast Cancer
RecruitingPhase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
Active, not recruitingPhase 2
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
Breast Cancer Stage IV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer and Breast Cancer Survivors, run by Cedars-Sinai Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Min Jung Sung, BA (424-315-0709, minjung.sung@cshs.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of peer-support platform engagement (time frame: Week 1 to Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.